高级检索
当前位置: 首页 > 详情页

NCOA6 knockdown enhances RSL3-induced ferroptosis in pancreatic cancer cells and increases the sensitivity to gemcitabine

文献详情

资源类型:
Pubmed体系:

收录情况: ◇ 统计源期刊 ◇ 卓越:梯队期刊

机构: [1]Department of Hepatobiliary Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050000, China, [2]Department of Emergency, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050000, China, [3]Department of Clinical Laboratory, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050000, China, [4]Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center, Shanghai 200031, China, [5]Pancreatic Cancer Institute, Fudan University, Shanghai 200031, China [6]Hebei Province Key Laboratory of Precision Diagnosis and Therapy for Hepatobiliary-Pancreatic Malignancies, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050000, China
出处:
ISSN:

摘要:
Ferroptosis is a type of programmed death characterized by iron-dependent lipid peroxidation, and targeting ferroptosis has been shown to efficiently kill highly aggressive cancer cells. Previously, we confirmed that nuclear receptors regulate ferroptosis in pancreatic cancer. However, whether nuclear receptor co-activators regulate ferroptosis is unclear. Here, we show that knocking down the nuclear receptor co-activator, NCOA6, enhances the sensitivity of pancreatic cancer cells to ferroptosis. Mechanistically, NCOA6 knockdown promotes the expression of ACSL4 while inhibiting the expression of SCD1, resulting in changes in lipid metabolism, sensitivity to RSL3-induced ferroptosis, and sensitivity to gemcitabine in pancreatic cancer. The relationships between NCOA6 and ACSL4 or SCD1 are further explored in clinical specimens. This study reveals that targeting NCOA6 might alleviate gemcitabine resistance in pancreatic cancer.

基金:
语种:
PubmedID:
中科院分区:
出版当年[2025]版:
大类 | 2 区 生物学
小类 | 2 区 生化与分子生物学 2 区 生物物理
最新[2025]版:
大类 | 2 区 生物学
小类 | 2 区 生化与分子生物学 2 区 生物物理
第一作者:
第一作者机构: [1]Department of Hepatobiliary Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050000, China, [6]Hebei Province Key Laboratory of Precision Diagnosis and Therapy for Hepatobiliary-Pancreatic Malignancies, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050000, China
共同第一作者:
通讯作者:
通讯机构: [1]Department of Hepatobiliary Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050000, China, [4]Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center, Shanghai 200031, China, [5]Pancreatic Cancer Institute, Fudan University, Shanghai 200031, China [6]Hebei Province Key Laboratory of Precision Diagnosis and Therapy for Hepatobiliary-Pancreatic Malignancies, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050000, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:42313 今日访问量:0 总访问量:1365 更新日期:2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号